Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Sep;26(3):253–259. doi: 10.1111/j.1365-2125.1988.tb05274.x

Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

P N Patsalos 1, J S Duncan 1, S D Shorvon 1
PMCID: PMC1386536  PMID: 3179165

Abstract

1. Antipyrine (AP) clearance, half-life and volume of distribution were determined in 52 patients, taking one or more antiepileptic drug (AED), before and 4 weeks after the complete removal of phenytoin (PHT, n = 20), carbamazepine (CBZ, n = 15) and sodium valproate (VPA, n = 17). 2. PHT removal was associated with a mean 13% fall in AP clearance and a mean 16% increase in AP half-life, in patients who were also taking CBZ with or without barbiturates. There was no significant difference between patients who did, and did not, take barbiturates, in addition to CBZ. 3. CBZ removal was associated with a mean 45% fall in AP clearance and a mean 69% increase in AP half-life, if there was no inducing AED comedication, but had no effect on AP clearance and half-life if PHT and/or barbiturates were also being taken. 4. Removal of VPA had no effect on AP clearance or half-life. 5. The removal of PHT, CBZ and VPA had no significant effect on AP volume of distribution. 6. PHT appears to be a more powerful inducer of hepatic enzyme activity, as measured by the AP test, than is CBZ.

Full text

PDF
253

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boobis A. R., Brodie M. J., Kahn G. C., Toverud E. L., Blair I. A., Murray S., Davies D. S. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol. 1981 Dec;12(6):771–777. doi: 10.1111/j.1365-2125.1981.tb01305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruni J., Wilder B. J., Perchalski R. J., Hammond E. J., Villarreal H. J. Valproic acid and plasma levels of phenobarbital. Neurology. 1980 Jan;30(1):94–97. doi: 10.1212/wnl.30.1.94. [DOI] [PubMed] [Google Scholar]
  3. Døssing M., Pilsgaard H., Rasmussen B., Poulsen H. E. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol. 1983;25(2):215–222. doi: 10.1007/BF00543794. [DOI] [PubMed] [Google Scholar]
  4. Kapetanović I. M., Kupferberg H. J., Porter R. J., Theodore W., Schulman E., Penry J. K. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981 Apr;29(4):480–486. doi: 10.1038/clpt.1981.66. [DOI] [PubMed] [Google Scholar]
  5. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia. 1984;25 (Suppl 2):S118–S131. doi: 10.1111/j.1528-1157.1984.tb05644.x. [DOI] [PubMed] [Google Scholar]
  6. Lai A. A., Levy R. H., Cutler R. E. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther. 1978 Sep;24(3):316–323. doi: 10.1002/cpt1978243316. [DOI] [PubMed] [Google Scholar]
  7. Moreland T. A., Park B. K., Rylance G. W. Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6 beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity. Br J Clin Pharmacol. 1982 Dec;14(6):861–865. doi: 10.1111/j.1365-2125.1982.tb02050.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ohnhaus E. E., Gerber-Taras E., Park B. K. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol. 1983;24(2):247–250. doi: 10.1007/BF00613826. [DOI] [PubMed] [Google Scholar]
  9. Oxley J., Hedges A., Makki K. A., Monks A., Richens A. Lack of hepatic enzyme inducing effect of sodium valproate. Br J Clin Pharmacol. 1979 Aug;8(2):189–190. doi: 10.1111/j.1365-2125.1979.tb05821.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Park B. K. Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol. 1982 Nov;14(5):631–651. doi: 10.1111/j.1365-2125.1982.tb04950.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Park B. K., Wilson A. C., Kaatz G., Ohnhaus E. E. Enzyme induction by phenobarbitone and vitamin K1 disposition in man. Br J Clin Pharmacol. 1984 Jul;18(1):94–97. doi: 10.1111/j.1365-2125.1984.tb05028.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Perucca E., Hedges A., Makki K. A., Richens A. A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. Br J Clin Pharmacol. 1980 Nov;10(5):491–497. doi: 10.1111/j.1365-2125.1980.tb01794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Perucca E., Hedges A., Makki K. A., Ruprah M., Wilson J. F., Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol. 1984 Sep;18(3):401–410. doi: 10.1111/j.1365-2125.1984.tb02482.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Petruch F., Schüppel R. V., Steinhilber G. Effect of diphenylhydantoin on hepatic drug hydroxylation. Eur J Clin Pharmacol. 1974 Jul 26;7(4):281–285. doi: 10.1007/BF00560345. [DOI] [PubMed] [Google Scholar]
  15. Rapeport W. G., McInnes G. T., Thompson G. G., Forrest G., Park B. K., Brodie M. J. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol. 1983 Aug;16(2):133–137. doi: 10.1111/j.1365-2125.1983.tb04976.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rimmer E. M., Routledge P. A., Tsanaclis L. M., Richens A. Pharmacokinetics of antipyrine in epileptic patients. Br J Clin Pharmacol. 1986 May;21(5):511–514. doi: 10.1111/j.1365-2125.1986.tb02833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Roberts C. J., Jackson L., Halliwell M., Branch R. A. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol. 1976 Oct;3(5):907–913. doi: 10.1111/j.1365-2125.1976.tb00646.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shaw P. N., Houston J. B., Rowland M., Hopkins K., Thiercelin J. F., Morselli P. L. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. Br J Clin Pharmacol. 1985 Dec;20(6):611–618. doi: 10.1111/j.1365-2125.1985.tb05119.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zielinski J. J., Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit. 1987;9(1):21–23. doi: 10.1097/00007691-198703000-00004. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES